Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LTRN – Lantern Pharma Inc

Lantern Pharma Inc.
LTRN
$3.35
Name : Lantern Pharma Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $36,128,744.00
EPSttm : -1.84
finviz dynamic chart for LTRN
Lantern Pharma Inc.
$3.35
0.45%
$0.015

Float Short %

3.14

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

EPS Last/This Y

0.1

EPS This/Next Y

0.28

Price

3.43

Target Price

22

Analyst Recom

1

Performance Q

-11.83

Relative Volume

1.21

Beta

1.54

Ticker: LTRN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07LTRN4.360.180.00422
2025-05-08LTRN3.850.180.00422
2025-05-09LTRN3.980.180.00421
2025-05-12LTRN4.120.160.01455
2025-05-13LTRN4.10.120.00588
2025-05-14LTRN4.060.120.00594
2025-05-15LTRN3.920.120.00597
2025-05-16LTRN3.340.062.48567
2025-05-19LTRN3.560.203.50443
2025-05-20LTRN3.470.203.50443
2025-05-21LTRN3.320.225.00451
2025-05-22LTRN3.310.210.00455
2025-05-23LTRN3.260.210.00455
2025-05-27LTRN2.90.18999.99523
2025-05-28LTRN2.880.180.00527
2025-05-29LTRN3.110.180.00527
2025-05-30LTRN3.120.180.00528
2025-06-02LTRN3.190.180.00529
2025-06-03LTRN3.220.170.00549
2025-06-04LTRN3.340.170.00550
2025-06-05LTRN3.420.1750.00549
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07LTRN4.343.9- -1.99
2025-05-08LTRN3.913.9- -1.99
2025-05-09LTRN3.983.9- -1.99
2025-05-12LTRN4.113.9- -1.99
2025-05-13LTRN4.113.9- -1.99
2025-05-14LTRN4.153.9- -1.99
2025-05-15LTRN3.873.9- -1.99
2025-05-16LTRN3.413.9- -1.99
2025-05-19LTRN3.593.9- -1.84
2025-05-20LTRN3.48- - -1.84
2025-05-21LTRN3.37- - -1.84
2025-05-22LTRN3.32- - -1.84
2025-05-23LTRN3.21- - -1.84
2025-05-27LTRN2.90- - -1.82
2025-05-28LTRN2.89- - -1.82
2025-05-29LTRN3.09- - -1.82
2025-05-30LTRN3.05- - -1.82
2025-06-02LTRN3.16- - -1.82
2025-06-03LTRN3.22- - -1.82
2025-06-04LTRN3.34- - -1.82
2025-06-05LTRN3.43- - -1.82
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07LTRN0.001.783.40
2025-05-08LTRN0.001.783.40
2025-05-09LTRN0.001.783.40
2025-05-12LTRN0.001.593.17
2025-05-13LTRN0.001.593.17
2025-05-14LTRN0.001.593.17
2025-05-15LTRN0.001.593.17
2025-05-16LTRN0.001.593.17
2025-05-19LTRN0.001.393.17
2025-05-20LTRN0.001.393.17
2025-05-21LTRN0.001.393.17
2025-05-22LTRN0.001.393.17
2025-05-23LTRN0.001.393.17
2025-05-27LTRN0.00-4.873.17
2025-05-28LTRN0.00-4.873.17
2025-05-29LTRN0.00-4.873.17
2025-05-30LTRN-3.92-4.873.17
2025-06-02LTRN-3.93-4.873.17
2025-06-03LTRN-3.93-4.873.17
2025-06-04LTRN-4.05-4.873.14
2025-06-05LTRN-4.04-4.873.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.48

Avg. EPS Est. Next Quarter

-0.44

Insider Transactions

-4.04

Institutional Transactions

-4.87

Beta

1.54

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

20

Sentiment Score

39

Actual DrawDown %

86.2

Max Drawdown 5-Year %

Target Price

22

P/E

Forward P/E

PEG

P/S

P/B

2.2

P/Free Cash Flow

EPS

-1.84

Average EPS Est. Cur. Y​

-1.82

EPS Next Y. (Est.)

-1.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.21

Return on Equity vs Sector %

-142.5

Return on Equity vs Industry %

-124.7

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.16

EBIT Estimation

Lantern Pharma Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 24
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
stock quote shares LTRN – Lantern Pharma Inc Stock Price stock today
news today LTRN – Lantern Pharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LTRN – Lantern Pharma Inc yahoo finance google finance
stock history LTRN – Lantern Pharma Inc invest stock market
stock prices LTRN premarket after hours
ticker LTRN fair value insiders trading